Modern and multidisciplinary care in polycythemia vera
Open Access
- 18 April 2026
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (5) , 251
Abstract
Polycythemia Vera (PV) is a chronic, BCR::ABL1 -negative, myeloproliferative neoplasm characterized by increased hematocrit and platelet/leukocyte counts, as well as by a high risk of thrombosis and progression to myelofibrosis and acute leukemia. The initial discovery of the JAK2 V617F driver mutation, followed by a more in-depth knowledge of the mechanisms that regulate inflammation and iron homeostasis, significantly advanced our understanding of PV pathophysiology, paving the way for a shift from symptom-focused vs. biology-focused treatments. PV management is complex and should be individualized, considering age, comorbidities, clinical presentation, disease course, and patient preferences. As such, optimal care requires a dynamic approach involving coordinated collaboration among healthcare professionals, in order to reduce complications, and enhance patients’ quality of life and outcomes. This narrative review explores principles and benefits of integrated care for PV patients, illustrated through two representative clinical cases. We propose that a transdisciplinary approach be adopted throughout the diagnostic and therapeutic continuum for PV to optimize patient outcomes. The review also proposes a novel cytoreductive treatment algorithm in PV going beyond the conventional risk stratification based on patient’s age and history of thrombosis but rather focusing on patient’s characteristics and treatment needs. Finally, we examine ongoing clinical studies and the latest results and insights on PV therapies (including the JAK inhibitor ruxolitinib, the next-generation mono-pegylated type I interferon ropeginterferon alfa-2b, the iron metabolism modifiers and other experimental approaches) that could reshape the standard of care in PV.Keywords
Funding Information
- Alma Mater Studiorum - Università di Bologna
This publication has 152 references indexed in Scilit:
- The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic CorrelatesAmerican Journal of Hematology, 2025
- Topics of Interest in Women With Myeloproliferative NeoplasmsAmerican Journal of Hematology, 2025
- Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemiaAmerican Journal of Hematology, 2024
- Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategiesAmerican Journal of Hematology, 2023
- Myeloproliferative neoplasms and pregnancy: Overview and practice recommendationsAmerican Journal of Hematology, 2020
- A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched studyAmerican Journal of Hematology, 2017
- Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasmsAmerican Journal of Hematology, 2016
- The effect of arterial hypertension on thrombosis in low‐risk polycythemia veraAmerican Journal of Hematology, 2016
- Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPNAmerican Journal of Hematology, 2012